DEC 04, 2015 12:15 PM PST

Light Zones, Dark Zones, and Lymphoma Formation

WRITTEN BY: Kara Marker
The germinal center of the immune system plays a complicated dual role in the body: vitally selecting B cells secreting high-affinity antibodies to serve the immune system in the fight against foreign invaders, and being the origin of most B cell lymphomas (Nature). 

From the Max Delbruck Center for Molecular Medicine (MDC) in Berlin, Klaus Rajewsky, PhD, and his team are looking into how various transcription factors and signaling pathways of the germinal center are taken over and manipulated during tumor growth and development. 

The germinal center contains reactions between a 'light zone' and a 'dark zone.' The dark zone generates B cells, and the light zone chooses the best candidates to mount an efficient immune response when a pathogen is detected in the body. Rajewsky's group investigated the role of transcription factor "forkhead box O1" (FOXO1), whose specific function has not yet been determined, in dark zone formation and looked for a potential connection to B cells of the germinal center (NIH).
Typical interactions of the germinal center (left) versus abnormal germinal center formation in FOXO1-deficient mice

The scientists used genetically modified mice to pinpoint the precise link between FOXO1 activity, germinal center B cells, and cancer cell formation. How can these interactions be manipulating cancer formation, they asked. Their findings, published in Immunity, showed that FOXO1 is necessary for an efficient immune response to pathogens, and the error leading to cancer development remains somewhere between FOXO1 and lymphomagenesis. 

Most B cell lymphomas arise from germinal B cells. Even more, FOXO1 mutations have been found to be activated in lymphoma patients.The team from MDC has yet to explain the specific connection between FOXO1 and cancer growth, but the relationship is clearly there. 

Watch the following video from the Lymphoma Research Foundation to learn more about a specific type of B cell lymphoma.

Source: MDC in the Helmholtz Association
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 23, 2021
Cardiology
Curbing Adverse Cardiovascular Outcomes Through Influenza Vaccination
SEP 23, 2021
Curbing Adverse Cardiovascular Outcomes Through Influenza Vaccination
Influenza is a severe infectious disease. According to the Centers for Disease Control and Prevention the H1N1 strain of ...
OCT 19, 2021
Immunology
Mild COVID Produces Better Than Expected Antibody Responses
OCT 19, 2021
Mild COVID Produces Better Than Expected Antibody Responses
Over millions of years, the immune system has evolved to shield us against disease-causing pathogens that we encounter e ...
NOV 11, 2021
Immunology
Malaria Researchers Make a Surprising Antibody Find
NOV 11, 2021
Malaria Researchers Make a Surprising Antibody Find
Researchers looking into the immunology of malaria infections have made an unexpected find that could ultimately lead to ...
NOV 11, 2021
Immunology
Some Patients Left Vulnerable to COVID Even After Getting Vaccinated
NOV 11, 2021
Some Patients Left Vulnerable to COVID Even After Getting Vaccinated
Global vaccination efforts continue in the backdrop of the ongoing pandemic. However, new studies demonstrate how severa ...
NOV 08, 2021
Health & Medicine
COVID-19 Vaccines Approved for Children 5-11
NOV 08, 2021
COVID-19 Vaccines Approved for Children 5-11
It has been a long time coming. COVID-19 vaccinations from Pfizer, Moderna, and Johnson and Johnson were offered to all ...
DEC 02, 2021
Microbiology
A 'Bispecific Antibody' to Fight Crimean-Congo Hemorrhagic Fever
DEC 02, 2021
A 'Bispecific Antibody' to Fight Crimean-Congo Hemorrhagic Fever
Crimean-Congo hemorrhagic fever (CCHF) is a deadly disease, which is fatal in about 30 percent of cases. It's caused ...
Loading Comments...